EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Abemaciclib plus endocrine therapy versus chemotherapy after progression on prior palbociclib in HR+/HER2‐ metastatic breast cancer: A single center real‐world study in China

Hanfang Jiang iD, Jianxin Zhong, Jing Wang, Guohong Song, Lijun Di, Bin Shao, Ruyan Zhang, Yaxin Liu iD, Anjie Zhu, Nan Wang, Huiping Li iD

Cancer Medicine · 2024

DOI: 10.1002/cam4.7249 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Cancer Medicine, 2024. Verfasst von Hanfang Jiang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Breast Oncology, Peking University Cancer Hospital…. Hauptthemen laut MEDLINE: Aminopyridines, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Piperazines. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Beijing Medical Award Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cyclin‐dependent kinase (CDK) 4/6 inhibitor plus endocrine therapy (ET) become standard‐of‐care for patients with hormone receptor‐positive, human epidermal growth factor receptor‐2 negative (HR+/HER2−) metastatic breast cancer (MBC). However, the optimal therapeutic paradigm after progression on CDK4/6 inhibitor remains unclear. This study aimed to evaluate the efficacy and safety of abemaciclib with switching ET versus chemotherapy after progression on prior palbociclib‐based ET in Chinese patients with HR+/HER2− MBC.

Methods

From 414 consecutive patients with HR+/HER2− MBC who had been treated with palbociclib plus ET from September 2018 to May 2022 in Peking University Cancer Hospital, we identified 80 patients who received abemaciclib plus switching ET or chemotherapy after progression on palbociclib, matched for age, original stage at diagnosis, disease‐free interval, and tumor burden at 1:1 ratio. The primary endpoint was progression‐free survival (PFS) compared using the Kaplan–Meier method. A Cox proportional hazard model was performed to identify clinical factors associated with PFS in the abemaciclib group.

Results

The median PFS was 6.0 months (95% confidence interval [CI]: 3.94–8.06) in abemaciclib group and 4.0 months (95% CI, 2.52–5.49) in chemotherapy group ( p = 0.667). And, there was no difference in median PFS between the sequential and nonsequential arm (6.0 vs. 6.0 months) in the abemaciclib group though fewer lines of prior systemic therapy and longer PFS from prior palbociclib in the sequential arm. However, patients with prior palbociclib as the first‐line therapy had a significantly longer median PFS versus prior palbociclib as ≥2nd‐line therapy (11.0 vs. 5.0 months, p = 0.043). Based on multivariable analysis, ER+/PR+ was an independent factor associated with longer PFS. There was no significant difference in overall survival between the abemaciclib and chemotherapy groups ( p = 0.069).

Conclusion

Our findings indicate that abemaciclib plus switching ET might be one of feasible treatment options for Chinese patients with HR+/HER2− MBC after progression on prior palbociclib‐based therapy in addition to chemotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AminopyridinesAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsPiperazinesErb-b2 Receptor Tyrosine KinasesReceptors, EstrogenAdultAgedFemaleHumansMiddle AgedAntineoplastic Agents, HormonalBenzimidazolesChinaDisease ProgressionProgression-Free SurvivalPyridinesReceptors, ProgesteroneRetrospective Studies

Stichwörter der Autor:innen

abemaciclibchemotherapyendocrine therapyhormone receptor‐positivemetastatic breast cancerpalbociclib progression

Substanzen

AminopyridinesAntineoplastic Agents, HormonalBenzimidazolesPiperazinesPyridinesErb-b2 Receptor Tyrosine KinasesReceptors, EstrogenReceptors, ProgesteroneabemaciclibERBB2 protein, human

Autor:innen und Institutionen

  • Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Breast Oncology, Peking University Cancer Hospital & Institute, Beijing, China.

ORCID-Profile: Hanfang Jiang, Yaxin Liu, Huiping Li

Förderung

  • Beijing Medical Award Foundation

Zitieren

APA

Jiang, H., Zhong, J., Wang, J., Song, G., Di, L., Shao, B., Zhang, R., Liu, Y., Zhu, A., Wang, N., & Li, H. (2024). Abemaciclib plus endocrine therapy versus chemotherapy after progression on prior palbociclib in HR+/HER2‐ metastatic breast cancer: A single center real‐world study in China. Cancer Medicine. https://doi.org/10.1002/cam4.7249

Vancouver

Jiang H, Zhong J, Wang J, Song G, Di L, Shao B, et al. Abemaciclib plus endocrine therapy versus chemotherapy after progression on prior palbociclib in HR+/HER2‐ metastatic breast cancer: A single center real‐world study in China. Cancer Medicine. 2024. doi:10.1002/cam4.7249

BibTeX
@article{Jiang2024,
  author = {Jiang, Hanfang and Zhong, Jianxin and Wang, Jing and Song, Guohong and Di, Lijun and Shao, Bin and Zhang, Ruyan and Liu, Yaxin and Zhu, Anjie and Wang, Nan and Li, Huiping},
  title = {Abemaciclib plus endocrine therapy versus chemotherapy after progression on prior palbociclib in HR+/HER2‐ metastatic breast cancer: A single center real‐world study in China},
  journal = {Cancer Medicine},
  year = {2024},
  doi = {10.1002/cam4.7249}
}
Kostenlos starten →